Rima Acosta

机构：Brigham and Women's Hospital, Chestnut Hill College · ORCID：0000-0002-0255-9487

发表论文 26 篇 · 总被引 1214 次 · h-index 14

代表论文

• Neutralization, effector function and immune imprinting of Omicron variants (2023 · Nature · 被引 182)
• Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial (2019 · The Lancet HIV · 被引 168)
• Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial (2019 · The Lancet HIV · 被引 146)
• Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials (2020 · The Lancet HIV · 被引 142)
• Switching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically Suppressed Adults With Human Immunodeficiency Virus (2020 · Clinical Infectious Diseases · 被引 116)
• Bictegravir/emtricitabine/tenofovir alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trials (2023 · EClinicalMedicine · 被引 90)